Bile acid levels climb during every pregnancy as a normal consequence of the hormonal shifts that sustain a growing fetus, but when those levels climb too high, a condition called intrahepatic cholestasis of pregnancy (ICP) develops and puts both mother and baby at risk. Total bile acids increase steadily from the first trimester through late pregnancy, with a particularly sharp shift in the bile acid profile around weeks 28 to 31. For most women, this rise stays within a range the body can handle. For roughly one to two in every hundred pregnancies, though, the system tips into cholestasis, and what follows demands prompt attention.
Why Bile Acids Rise During Normal Pregnancy
Pregnancy hormones are the main driver. Estrogen and progesterone, which surge to levels far beyond anything the body sees outside of pregnancy, directly interfere with the liver’s ability to move bile acids out of liver cells and into the bile ducts. Estrogen impairs the synthesis, metabolism, and transport of bile acids, reducing bile flow and disrupting the normal recycling loop between the liver and gut.1Frontiers in Pharmacology. The Pathological Mechanisms of Estrogen-Induced Cholestasis: Current Perspectives Progesterone metabolites add to the problem by blocking a key transporter on liver cells called the bile salt export pump (BSEP), which is the main exit route for bile acids leaving the liver.2Journal of Hepatology. Potential role of trans-inhibition of the bile salt export pump by progesterone metabolites in the etiopathogenesis of intrahepatic cholestasis of pregnancy
The bile acid profile itself changes character as pregnancy progresses. In the second trimester, unconjugated bile acids dominate. By the third trimester, conjugated forms, especially those bound to the amino acid taurine, take over.3PubMed. Characteristics of bile acids metabolism profile in the second and third trimesters of normal pregnancy The ratio of different bile acid species also shifts: cholic acid rises relative to chenodeoxycholic acid, and the overall total keeps climbing.4PubMed Central. Bile acids during pregnancy: Trimester variations and associations with glucose homeostasis These changes reflect the growing hormonal pressure on the liver’s bile-handling machinery, and in most pregnancies the liver manages to keep pace, even if circulating bile acid levels run higher than they would in a non-pregnant person.
When the Rise Becomes a Problem
ICP occurs when bile acids accumulate in the bloodstream to a degree that causes symptoms and threatens the pregnancy. The hallmark symptom is intense itching, usually worst on the palms of the hands and soles of the feet, and characteristically worse at night. About 77% of women with ICP report that itching intensifies after dark, and 94% experience significant sleep disturbance as a result.5PubMed Central. Impact of pruritus in patients at high risk of significant intrahepatic cholestasis of pregnancy Diagnosis rests on the combination of this characteristic itching and elevated total serum bile acids.
One quirk that complicates diagnosis: the correlation between bile acid levels and how badly someone itches is surprisingly weak.6PubMed. Relationship between pruritus and autotaxin in intrahepatic cholestasis of pregnancy A woman with moderately elevated bile acids can be clawing at her skin, while another with much higher levels may report only mild discomfort.7PubMed Central. Intrahepatic Cholestasis of Pregnancy: Role of Baby’s Sex on Itch Severity and Bile Acid Levels The itching in ICP appears to be driven partly by a molecule called autotaxin rather than bile acids alone, which explains the disconnect. That said, very high bile acid concentrations (at or above 100 µmol/L) are independently linked to worsening itch.8PubMed. Characteristics associated with alterations in pruritus severity across gestation in intrahepatic cholestasis of pregnancy: a longitudinal cohort study
Timing of blood draws matters. Bile acid levels spike after eating, and there is considerable overlap between healthy pregnant women and those with mild ICP when blood is drawn in a non-fasting state. Fasting measurements are more specific but miss a large share of mild cases. For identifying severe disease, defined as total bile acids at or above 40 µmol/L, a non-fasting measurement actually catches over 90% of cases, compared to only about 9% when fasting.9PubMed. Re-evaluating diagnostic thresholds for intrahepatic cholestasis of pregnancy: case-control and cohort study Seasonal variation adds another layer: bile acid levels in healthy pregnant women run highest during winter months.10PubMed Central. Intrahepatic cholestasis of pregnancy – Time to redefine the reference range of total serum bile acids: A cross-sectional study Your provider should take all of this context into account when interpreting a borderline result.
Who Is at Higher Risk
There is a clear genetic component. Researchers have identified several genes involved in bile acid transport that, when they carry certain variants, make a woman substantially more susceptible to ICP.11PubMed Central. The molecular genetics of intrahepatic cholestasis of pregnancy One well-studied gene is ABCB4, which encodes a protein that helps move phospholipids into bile. Women with ICP who carry certain ABCB4 variants tend to carry additional genetic changes that healthy carriers of the same variant do not have, suggesting these variants work together to push bile acid handling past a tipping point.12Scientific Reports. Association between ABCB4 variants and intrahepatic cholestasis of pregnancy
The working model is that genetics load the gun and hormones pull the trigger. Women who carry these transport-gene variants have a liver that functions fine under normal circumstances but cannot keep up once pregnancy hormones start interfering with bile flow. Estrogen metabolites and progesterone metabolites both contribute, and some researchers propose that a selective defect in how sulfated progesterone metabolites are secreted into bile may be the central bottleneck in genetically predisposed women.13PubMed. Bile acids and progesterone metabolites in intrahepatic cholestasis of pregnancy Environmental factors like diet, selenium status, and even the season of the year can modulate this interaction, which is why ICP sometimes appears in one pregnancy but not the next.
The Gut Microbiome’s Role
A growing body of research points to gut bacteria as an underappreciated player in pregnancy cholestasis. The gut microbiome of women with ICP looks meaningfully different from that of healthy pregnant women, and when researchers transplanted gut bacteria from ICP patients into mice, the mice developed cholestasis. The microbial profile in ICP is dominated by a species called Bacteroides fragilis, which produces an enzyme (bile salt hydrolase) that modifies bile acids in a way that suppresses a key sensor called FXR. FXR normally acts as a brake on bile acid production, so when it gets shut down, the liver keeps churning out bile acids while simultaneously exporting less of them into bile.14PubMed Central. Gut microbiota alters host bile acid metabolism to contribute to intrahepatic cholestasis of pregnancy
Interestingly, treatment with ursodeoxycholic acid (UDCA) may partially work through the microbiome. In cholestatic pregnancies, UDCA enriches the gut with bacteria from the Bacteroidetes group that have high bile salt hydrolase activity. These bacteria deconjugate bile acids in a way that creates compounds capable of switching FXR back on, potentially restoring the feedback loop that keeps bile acid production in check.15Scientific Reports. Ursodeoxycholic acid enriches intestinal bile salt hydrolase-expressing Bacteroidetes in cholestatic pregnancy This is still early science, but it suggests ICP may be as much about the gut as it is about the liver.
How Elevated Bile Acids Affect the Baby
Under normal conditions, the placenta acts as the baby’s liver for bile acid clearance, actively pumping bile acids from fetal blood back into the mother’s circulation. This process depends on carrier proteins on the fetal-facing surface of the placenta that preferentially transport certain bile acid species.16PubMed. Relationship between bile acid transplacental gradients and transport across the fetal-facing plasma membrane of the human trophoblast Multiple transporter families coordinate this effort, moving bile acids and related compounds across placental cells and into maternal blood.17Annals of Hepatology. Molecular bases of the excretion of fetal bile acids and pigments through the fetal liver-placenta-maternal liver pathway When the mother’s bile acid levels are high, this gradient reverses or stalls, and bile acids build up on the fetal side.
The fetal heart is a primary target. Elevated bile acids, particularly taurocholic acid, can slow electrical conduction through the baby’s heart by activating receptors that disrupt calcium signaling at the AV node, prolonging the time it takes for each heartbeat’s electrical signal to travel through the heart. Studies of ICP pregnancies show that fetal markers of cardiac stress correlate with bile acid levels in the fetal blood.18PubMed Central. Fetal cardiac dysfunction in intrahepatic cholestasis of pregnancy is associated with elevated serum bile acid concentrations In severe ICP, neonates have been found to have abnormally prolonged QRS intervals, indicating a higher rate of ventricular conduction problems compared to babies born from mild or non-cholestatic pregnancies.19bioRxiv. Toxic effects of elevated bile acid levels on fetal myocardium in intrahepatic cholestasis of pregnancy, a retrospective study from a neonatal perspective
Beyond the heart, high bile acids stimulate the fetal bowel, leading to meconium passage before birth. Meconium-stained amniotic fluid occurred in roughly 13% of ICP deliveries in one study, and the risk increased about fourfold when the ratio of bile acid measurements exceeded a certain threshold. Earlier onset and more severe bile acid elevations predicted higher meconium rates, and treatment with UDCA appeared to modify that association.20PubMed Central. Relationship between early onset severe intrahepatic cholestasis of pregnancy and higher risk of meconium-stained fluid ICP roughly doubles the overall risk of preterm birth and significantly increases the chance of meconium-stained amniotic fluid.21iLIVER. Intrahepatic cholestasis of pregnancy is associated with increased risk of hepatobiliary disease and adverse fetal outcomes: A systematic review and meta-analysis
Treatment With Ursodeoxycholic Acid
UDCA is the most widely used medication for ICP. It is itself a bile acid, but a comparatively gentle one. When taken, it comes to make up roughly 60 to 70% of the total bile acid pool, replacing the more toxic hydrophobic bile acids that do the real damage. It also improves bile flow, helps protect the lining of the bile ducts, and appears to reduce bile acid levels in the fetus, likely by boosting the placenta’s ability to pump bile acids back to the mother.22PubMed Central. Ursodeoxycholic acid in intrahepatic cholestasis of pregnancy: a systematic review and individual participant data meta-analysis
The evidence on how well UDCA works is, frankly, mixed. An earlier meta-analysis found it lowered bile acid levels, resolved itching in more women than controls, reduced premature births by about 44%, cut fetal distress, and decreased admissions to neonatal intensive care.23PubMed Central. Evaluating the effectiveness and safety of ursodeoxycholic acid in treatment of intrahepatic cholestasis of pregnancy: A meta-analysis But the largest single randomized controlled trial, called PITCHES, found no meaningful reduction in a composite of adverse perinatal outcomes and no clinically significant improvement in itch or bile acid levels compared to placebo.24The Lancet. Ursodeoxycholic acid versus placebo in women with intrahepatic cholestasis of pregnancy (PITCHES): a randomised controlled trial
A later individual-participant-data meta-analysis, which pooled data from multiple randomized controlled trials, found that UDCA did not significantly reduce stillbirth on its own. However, when the analysis was restricted to randomized trials only, UDCA was associated with a reduction in the combined outcome of stillbirth and preterm birth, providing some evidence of clinical benefit.25PubMed. Ursodeoxycholic acid in intrahepatic cholestasis of pregnancy: a systematic review and individual participant data meta-analysis So UDCA remains standard of care in many guidelines, but with the understanding that its benefits may be smaller than earlier studies suggested. It does appear to be safe, which matters when treating pregnant women.
For women with severe ICP who do not respond to UDCA alone, rifampicin, an antibiotic better known for treating tuberculosis, can be added. In a case series of severe ICP pregnancies where bile acids stayed high on UDCA, adding rifampicin brought levels down in over half the cases, and nearly 40% saw a reduction of 50% or more. No adverse effects were reported with the combination.26PubMed. Rifampicin in the treatment of severe intrahepatic cholestasis of pregnancy
When to Deliver
Delivery timing in ICP is a balancing act between the risks of continued fetal bile acid exposure and the risks of prematurity. Current guidelines from the Society for Maternal-Fetal Medicine stratify by bile acid level. For women with total bile acids at or above 100 µmol/L, delivery at 36 weeks is recommended, because the risk of stillbirth climbs steeply around that point. For women with bile acids below 100 µmol/L, delivery between 36 and 39 weeks is recommended.27American Journal of Obstetrics & Gynecology. SMFM Consult Series #53: Intrahepatic cholestasis of pregnancy The exact timing within that window depends on how well symptoms and bile acid levels are controlled, fetal monitoring results, and the clinical judgment of your provider.
The 100 µmol/L threshold is important to understand because it marks the boundary of the highest-risk group. Below that level, adverse outcomes are possible but much less common, and the conversation with your provider shifts from “we need to deliver soon” to a more nuanced weighing of factors.
The Psychological Toll
ICP is not just a liver problem. The relentless itching takes a serious toll on daily life. In a large survey of women at high risk of significant ICP, three-quarters reported that pruritus negatively affected their mood, including increased anxiety, hopelessness, and irritability. Nearly 60% said it disrupted their daily routines, and about a third missed work or school during episodes. The median severity score for sleep disturbance was 8 out of 10, and over 90% of affected women had significant sleep disruption.5PubMed Central. Impact of pruritus in patients at high risk of significant intrahepatic cholestasis of pregnancy Fatigue compounds the problem: among those who experienced tiredness beyond what their sleep loss would explain, 63% rated it as “much worse” than expected. If you are dealing with ICP, the mental health burden is real and worth discussing with your care team, not just the blood test numbers.
Distinguishing ICP From Other Causes of Itching
Not every itch during pregnancy is ICP. There are several pregnancy-specific skin conditions that cause itching, including conditions that produce rashes and visible skin changes. ICP is different because it is not a primary skin disease; the skin itself looks normal, and the itching comes from within. Any secondary skin changes, like scratch marks, are self-inflicted from scratching.28PubMed. Specific dermatoses of pregnancy: an evidence-based systematic review The absence of a rash, the predilection for palms and soles, and onset in the third trimester are the classic features that point your provider toward a bile acid blood test rather than a dermatology referral. That said, some women develop ICP earlier, and earlier-onset cases tend to be more severe, so the timing alone is not a reliable rule-out.
Long-Term Consequences for Mother and Child
ICP does not end at delivery for either party. For mothers, having had ICP is associated with roughly a threefold higher risk of later hepatobiliary disease, including gallstones, liver inflammation, and other bile-duct problems. The association with hepatitis C is even stronger, at about fourfold, though the reasons for that link are still debated and may partly reflect shared risk factors.21iLIVER. Intrahepatic cholestasis of pregnancy is associated with increased risk of hepatobiliary disease and adverse fetal outcomes: A systematic review and meta-analysis Women who have had ICP should be aware that their liver may warrant closer attention in the years that follow, particularly if they develop symptoms suggestive of gallbladder or biliary disease.
For children, two lines of evidence are emerging. A large Swedish study of over two million children found that those born to mothers with ICP were about 22% more likely to be diagnosed with a neurodevelopmental condition compared to unexposed children. The earlier the mother’s ICP was diagnosed during pregnancy, the stronger the association: ICP diagnosed before 28 weeks was linked to more than double the risk of neurodevelopmental conditions in the child, while ICP diagnosed after 37 weeks showed no significant increase.29PubMed Central. Maternal intrahepatic cholestasis of pregnancy and neurodevelopmental conditions in offspring: A population-based cohort study of 2 million Swedish children Separately, a study tracking the offspring of cholestatic pregnancies into adolescence found that by age 16, boys had higher BMI and fasting insulin, while girls had increased waist and hip measurements and lower HDL cholesterol, compared to peers from non-cholestatic pregnancies.30The Journal of Clinical Investigation. Maternal cholestasis during pregnancy programs metabolic disease in offspring These findings suggest that fetal bile acid exposure may have lasting metabolic and developmental effects, though the absolute risks remain modest and these are associations, not certainties about any individual child’s future.
The metabolic programming angle is particularly interesting because it echoes what researchers see in other prenatal exposures: the intrauterine environment can set metabolic trajectories that only become visible years later. For ICP offspring, this could mean a slightly higher baseline risk for metabolic syndrome-type features heading into adulthood. Whether early intervention, monitoring, or lifestyle guidance during childhood could offset this trajectory is a question nobody has answered yet.